Feasibility study on the continued use of axitinib/axitinib after drug resistance

Axitinib/Axitinib is an oral small molecule tyrosine kinase inhibitor mainly used to treat malignant tumors such as advanced renal cell carcinoma. However, resistance sometimes develops in patients receiving axitinib, prompting discussion about whether the drug should continue to be used.

First of all, the drug resistance mechanism is very complex and may involve multiple factors such as genetic mutations of tumor cells, changes in drug metabolism, and changes in the tumor microenvironment. When resistance develops, the efficacy of axitinib may be significantly reduced, and the need for continued use of the drug needs to be carefully evaluated. If the patient still retains some sensitivity to the drug after drug resistance, continued use at low doses may help delay the progression of the disease, but this decision must be made under the guidance of a professional physician.

Secondly, tumor characteristics and biomarker detection after drug resistance are particularly important. Through technical means such as gene sequencing, we can gain an in-depth understanding of the specific mechanisms of drug resistance and determine whether it is appropriate to continue using axitinib. Some studies have shown that for patients with specific genetic mutations, adjustments to treatment regimens may improve outcomes. Therefore, it is crucial to reassess a patient's tumor characteristics following drug resistance.

In addition, from a clinical practice perspective, drug resistance does not mean the end of treatment. In some cases, doctors may consider combining axitinib with other medications to enhance the effectiveness of treatment. For example, combining it with immunotherapy drugs or other targeted drugs may help overcome resistance issues and thereby improve patients' survival and quality of life.

Finally, the decision to continue using axitinib after resistance should follow the principle of individualized treatment. During this process, the patient's overall health, tumor progression rate, possible side effects, and response to new treatments should all be considered. Therefore, it is recommended that patients maintain close communication with their doctors to jointly develop appropriate follow-up treatment plans.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC6860026/